Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Amarin announces data from REDUCE-IT REVASC analysis of VASCEPA » 07:15
07/27/20
07/27
07:15
07/27/20
07:15
AMRN

Amarin

$6.51 /

-0.065 (-0.99%)

Amarin Corporation…

Amarin Corporation announced that data from the REDUCE-IT REVASC analysis, presented as an encore by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD Prevention, showed that administration of 4 g/day of VASCEPA resulted in a significant 34% reduction in first coronary revascularizations versus placebo. Similar reductions of 36% were observed in total, or first and subsequent, revascularizations. In newly presented data, an early coronary revascularization benefit signal was shown in a prespecified exploratory analysis, with sustained statistical significance attained by 11 months. Coronary revascularization procedures, such as stenting and coronary artery bypass grafts, are invasive, carry multiple risks, and can have significant direct and indirect costs. Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. These procedures, whether pre-scheduled or performed in an emergency, inevitably result in additional time spent in a healthcare setting. The analyses from the REDUCE-IT trial included several types of coronary revascularization in statin-treated patients with persistently elevated triglycerides, who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors. Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including elective, urgent, and emergent revascularizations, which were reduced by 32%, 34%, and 38%, respectively. In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention by 32% and CABG by 39% relative to placebo/ REDUCE-IT was not specifically powered to examine individual cardiovascular endpoints, therefore p-values presented for these revascularization analyses are nominal and exploratory with no adjustment for multiple comparisons. In addition, coronary revascularization as an endpoint can sometimes be considered subjective; however, these endpoints were adjudicated by an independent, blinded clinical endpoint committee. Results from the total coronary revascularization events analyses are consistent across the various recurrent event statistical models and are also consistent with the first coronary revascularization events results. Together, the REDUCE-IT first and total coronary revascularization events results support the robustness and consistency of the clinical benefit of VASCEPA therapy in reducing coronary revascularization. Funding from Amarin was provided to Brigham and Women's Hospital for Dr. Deepak L. Bhatt's work as the REDUCE-IT study chair and global principal investigator.

ShowHide Related Items >><<
AMRN Amarin
$6.51 /

-0.065 (-0.99%)

AMRN Amarin
$6.51 /

-0.065 (-0.99%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.51 /

-0.065 (-0.99%)

AMRN Amarin
$6.51 /

-0.065 (-0.99%)

AMRN Amarin
$6.51 /

-0.065 (-0.99%)

AMRN Amarin
$6.51 /

-0.065 (-0.99%)

Hot Stocks
CADTH committee recommends reimbursement for Amarin's Vascepa » 16:01
07/20/20
07/20
16:01
07/20/20
16:01
AMRN

Amarin

$6.59 /

-0.105 (-1.57%)

The CADTH Canadian Drug…

The CADTH Canadian Drug Expert Committee recommends that icosapent ethyl be reimbursed to reduce the risk of CV events in statin-treated patients with elevated triglycerides, if certain conditions are met, according to a final recommendation document posted to the CADTH site. Icosapent ethyl is marketed under the brand name Vascepa. Reference Link

ShowHide Related Items >><<
AMRN Amarin
$6.59 /

-0.105 (-1.57%)

AMRN Amarin
$6.59 /

-0.105 (-1.57%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.59 /

-0.105 (-1.57%)

AMRN Amarin
$6.59 /

-0.105 (-1.57%)

AMRN Amarin
$6.59 /

-0.105 (-1.57%)

AMRN Amarin
$6.59 /

-0.105 (-1.57%)

Over a month ago
Syndicate
Matinas BioPharma files $200M mixed securities shelf  17:44
07/02/20
07/02
17:44
07/02/20
17:44
MTNB

Matinas BioPharma

$0.77 /

-0.0071 (-0.92%)

 
ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.77 /

-0.0071 (-0.92%)

MTNB Matinas BioPharma
$0.77 /

-0.0071 (-0.92%)

03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
01/24/20
Fly Intel: Top five analyst initiations
MTNB Matinas BioPharma
$0.77 /

-0.0071 (-0.92%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.77 /

-0.0071 (-0.92%)

Hot Stocks
Matinas BioPharma commences ENHANCE-IT enrollment, expects to resume EnACT » 16:20
06/30/20
06/30
16:20
06/30/20
16:20
MTNB

Matinas BioPharma

$0.77 /

-0.0144 (-1.83%)

Matinas BioPharma…

Matinas BioPharma announced that it has commenced enrollment and started dosing patients in the ENHANCE-IT study and that it expects to resume dosing patients in the EnACT study imminently, following the recent receipt of necessary governmental and regulatory approvals in Uganda. Both studies had temporarily paused enrollment in March due to the COVID-19 pandemic.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.77 /

-0.0144 (-1.83%)

MTNB Matinas BioPharma
$0.77 /

-0.0144 (-1.83%)

03/31/20 Piper Sandler
Matinas BioPharma price target lowered to $1.50 from $3.00 at Piper Sandler
01/27/20
Fly Intel: Top five analyst initiations
01/26/20 Piper Sandler
Matinas BioPharma initiated with an Overweight at Piper Sandler
01/24/20
Fly Intel: Top five analyst initiations
MTNB Matinas BioPharma
$0.77 /

-0.0144 (-1.83%)

  • 10
    Jan
MTNB Matinas BioPharma
$0.77 /

-0.0144 (-1.83%)

Conference/Events
Cantor Fitzgerald pharmaceuticals analysts hold analyst/industry conference call » 10:43
06/29/20
06/29
10:43
06/29/20
10:43
AMRN

Amarin

$6.67 /

-0.025 (-0.37%)

Pharmaceuticals Analysts,…

Pharmaceuticals Analysts, along with Zachary Silbersher, the founding partner of Kroub, Silbersher & Kolmykov (KSK), PLLC, discuss the likelihood that Amarin will win its appeal for Vascepa on an Analyst/Industry conference call to be held on June 29 at 11 am.

ShowHide Related Items >><<
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

  • 19
    Jul
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

Options
Notable open interest changes for June 23rd » 08:55
06/23/20
06/23
08:55
06/23/20
08:55
AAPL

Apple

$359.08 /

+9.53 (+2.73%)

, AMRN

Amarin

$7.13 /

+0.22 (+3.18%)

, BAC

Bank of America

$24.62 /

-0.34 (-1.36%)

, AAL

American Airlines

$14.91 /

-1.085 (-6.78%)

Monday's total…

Monday's total option volume of 25.5 million contracts resulted in net open interest growth of 4.84 million calls and 3.73 million puts. Apple (AAPL), Amarin (AMRN), Bank of America (BAC) and American Airlines (AAL) saw the greatest growth. Top five new positions opened include 51k Ford (F) Aug-20 6 puts, 27k Amarin (AMRN) Sep-20 7 calls, 22k Amarin (AMRN) Sep-20 10 calls, 20k Amarin (AMRN) Sep-20 6 puts and 20k US Steel (X) Aug-20 7 puts.

ShowHide Related Items >><<
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

06/23/20 Credit Suisse
Apple launches at WWDC more incremental than thesis-changing, says Credit Suisse
06/23/20 Oppenheimer
Apple creating 'wide moat' for own ecosystem, says Oppenheimer
06/23/20 Goldman Sachs
Apple's revamped Mac rollout plans look aggressive, says Goldman Sachs
AMRN Amarin
$7.13 /

+0.22 (+3.18%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

06/11/20 BTIG
First Department ruling 'a significant positive' for Ambac Financial, says BTIG
06/05/20 Wells Fargo
Bank of America price target raised to $35 from $30 at Wells Fargo
04/16/20 DA Davidson
Bank of America price target raised to $26 from $24 at DA Davidson
04/16/20 BMO Capital
Bank of America price target lowered to $24 from $26 at BMO Capital
AAL American Airlines
$14.91 /

-1.085 (-6.78%)

06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

  • 23
    Jun
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

Options
Unusual call flow in option market yesterday » 07:35
06/23/20
06/23
07:35
06/23/20
07:35
X

U.S. Steel

$8.05 /

-0.06 (-0.74%)

, AMRN

Amarin

$7.13 /

+0.22 (+3.18%)

Notable call activity was…

Notable call activity was cited Monday in US Steel (X) and Amarin (AMRN).

ShowHide Related Items >><<
X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

06/09/20 GLJ Research
U.S. Steel upgraded to Hold from Sell at GLJ Research
03/23/20 BMO Capital
U.S. Steel price target lowered to $6 from $9 at BMO Capital
01/31/20 BMO Capital
U.S. Steel price target lowered to $10 from $14 at BMO Capital
01/14/20 Goldman Sachs
U.S. Steel reinstated with a Sell at Goldman Sachs
AMRN Amarin
$7.13 /

+0.22 (+3.18%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

Options
Double spread collar in Amarin opens bullish position » 12:00
06/22/20
06/22
12:00
06/22/20
12:00
AMRN

Amarin

$6.82 /

-0.095 (-1.37%)

Double spread collar in…

Double spread collar in Amarin opens bullish position. Shares little changed this morning near $6.80 with a 4-way spread on the ISE where a customer appears to have sold the Sep 5/6 put spread to buy the Sep 7/10 call spread a total of 20k times, opening on all legs. For the largest tranche of 15k, the net credit on the put spread was 27c and the debit on the call spread 77c, for a net debit of 50c, or about $1M on the package. Net delta on the package is nearly 670k shares, or 9% the average daily turnover in the name. Amarin shares dropped nearly 70% from over $13 to $4 on March 31 related to a court ruling. Today's trade could return a 500% gain to the buyer if shares were to return to double digit territory over the next three months.

ShowHide Related Items >><<
AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

Recommendations
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink » 09:12
06/17/20
06/17
09:12
06/17/20
09:12
AMRN

Amarin

$6.88 /

+0.03 (+0.44%)

, RDY

Dr. Reddy's

$53.06 /

-0.69 (-1.28%)

SVB Leerink analyst Ami…

SVB Leerink analyst Ami Fadia notes that Amarin (AMRN) has settled Vascepa patent litigation with Apotex. While the analyst doesn't believe the U.S. Vascepa patent litigation settlement with Apotex provides any readthrough on the strength of Amarin's case in the ongoing appeal versus Hikma and Dr. Reddy's (RDY), it consolidates the fate of Apotex with the other generic filers and gives Amarin greater clarity on how generic competition in the U.S. will shape up post the appeals ruling. Fadia thinks the settlement puts more at stake for Amarin, and reflects management doubling down on the strength of its appeal's case, although she doesn't disagree with the decision given the risk/reward on the appeal is heavily skewed to the upside. The analyst continues to assign a 20% Probability of Success that Amarin wins the appeal. Fadia has an Outperform rating on Amarin's shares.

ShowHide Related Items >><<
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
03/13/20 Goldman Sachs
Amarin upgraded to Buy from Neutral at Goldman Sachs
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

Recommendations
Amarin settlement with Apotex an 'incremental positive,' says Stifel » 08:28
06/17/20
06/17
08:28
06/17/20
08:28
AMRN

Amarin

$6.88 /

+0.03 (+0.44%)

, RDY

Dr. Reddy's

$53.06 /

-0.69 (-1.28%)

, TEVA

Teva

$12.05 /

+0.55 (+4.78%)

Stifel analyst Derek…

Stifel analyst Derek Archila reiterates his Hold rating on Amarin (AMRN) shares after the company settled with Apotex regarding its ANDA application for generic Vascepa. Apotex cannot sell a generic version of Vascepa until August 2029, which is the same date as Amarin's settlement with Teva (TEVA), noted Archila. While this settlement with another generic ANDA filer is an "incremental positive," Archila doesn't see this a major stock moving catalyst since Apotex is not a party in the ongoing appeal of the district court's decision invalidating Vascepa's patents, he tells investors. He expects Amarin shares to remain range-bound until closer to the hearing on the Hikma and Dr. Reddy's (RDY) case later this year, added Archila.

ShowHide Related Items >><<
TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
03/13/20 Goldman Sachs
Amarin upgraded to Buy from Neutral at Goldman Sachs
02/26/20 H.C. Wainwright
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results
TEVA Teva
$12.05 /

+0.55 (+4.78%)

06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 Truist
Teva upgraded to Buy from Hold at SunTrust
06/01/20 Truist
Teva upgraded to Buy from Hold at SunTrust
TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.